Works matching IS 17762596 AND DT 2015 AND VI 10 AND IP 3
Results: 14
Targeting epidermal growth factor receptors and downstream signaling pathways in cancer by phytochemicals.
- Published in:
- Targeted Oncology, 2015, v. 10, n. 3, p. 337, doi. 10.1007/s11523-014-0339-4
- By:
- Publication type:
- Article
Receptors for luteinizing hormone-releasing hormone (GnRH) as therapeutic targets in triple negative breast cancers (TNBC).
- Published in:
- Targeted Oncology, 2015, v. 10, n. 3, p. 365, doi. 10.1007/s11523-014-0340-y
- By:
- Publication type:
- Article
Comparison of tyrosine kinase receptors HER2, EGFR, and VEGFR expression in micropapillary urothelial carcinoma with invasive urothelial carcinoma.
- Published in:
- Targeted Oncology, 2015, v. 10, n. 3, p. 355, doi. 10.1007/s11523-014-0341-x
- By:
- Publication type:
- Article
Panitumumab as a radiosensitizing agent in KRAS wild-type locally advanced rectal cancer.
- Published in:
- Targeted Oncology, 2015, v. 10, n. 3, p. 375, doi. 10.1007/s11523-014-0342-9
- By:
- Publication type:
- Article
Prognostic factors in renal cell carcinoma patients treated with sorafenib: results from the Czech registry.
- Published in:
- Targeted Oncology, 2015, v. 10, n. 3, p. 385, doi. 10.1007/s11523-014-0343-8
- By:
- Publication type:
- Article
Afatinib resistance in non-small cell lung cancer involves the PI3K/AKT and MAPK/ERK signalling pathways and epithelial-to-mesenchymal transition.
- Published in:
- Targeted Oncology, 2015, v. 10, n. 3, p. 393, doi. 10.1007/s11523-014-0344-7
- By:
- Publication type:
- Article
Targeted delivery of siRNA using transferrin-coupled lipoplexes specifically sensitizes CD71 high expressing malignant cells to antibody-mediated complement attack.
- Published in:
- Targeted Oncology, 2015, v. 10, n. 3, p. 405, doi. 10.1007/s11523-014-0345-6
- By:
- Publication type:
- Article
Colorectal liver metastases are more often super wild type. Toward treatment based on metastatic site genotyping?
- Published in:
- Targeted Oncology, 2015, v. 10, n. 3, p. 415, doi. 10.1007/s11523-014-0346-5
- By:
- Publication type:
- Article
Everolimus in patients with metastatic renal cell carcinoma previously treated with bevacizumab: a prospective multicenter study CRAD001LRU02T.
- Published in:
- Targeted Oncology, 2015, v. 10, n. 3, p. 423, doi. 10.1007/s11523-014-0347-4
- By:
- Publication type:
- Article
Association of drug exposure with toxicity and clinical response in metastatic renal cell carcinoma patients receiving an attenuated dosing regimen of sunitinib.
- Published in:
- Targeted Oncology, 2015, v. 10, n. 3, p. 429, doi. 10.1007/s11523-014-0349-2
- By:
- Publication type:
- Article
Sunitinib does not attenuate contractile force following a period of ischemia in isolated human cardiac muscle.
- Published in:
- Targeted Oncology, 2015, v. 10, n. 3, p. 439, doi. 10.1007/s11523-014-0351-8
- By:
- Publication type:
- Article
Regorafenib: start low and go slow.
- Published in:
- Targeted Oncology, 2015, v. 10, n. 3, p. 445, doi. 10.1007/s11523-014-0352-7
- By:
- Publication type:
- Article
The route to personalized medicine in bladder cancer: where do we stand?
- Published in:
- Targeted Oncology, 2015, v. 10, n. 3, p. 325, doi. 10.1007/s11523-015-0357-x
- By:
- Publication type:
- Article
Treatment of advanced thyroid cancer: role of molecularly targeted therapies.
- Published in:
- Targeted Oncology, 2015, v. 10, n. 3, p. 311, doi. 10.1007/s11523-014-0331-z
- By:
- Publication type:
- Article